February 16, 2026
Legal Alert

On January 28, 2021, Janet Linn will moderate the CLE “Skinny Labels and Patent Infringement” for the NYSBA Food, Drug & Cosmetic Law Section Annual Meeting. During the CLE, the speakers will explore liability for induced patent infringement in light of the GSK v. Teva and Amarin v. Hikma & HealthNet decision. The panel will discuss avenues for insurers, PBMs, and pharmacies, as well as generic companies, to reduce the risk of being liable for infringement.
Learn more and register here.
On January 28, 2021, Janet Linn will moderate the CLE “Skinny Labels and Patent Infringement” for the NYSBA Food, Drug & Cosmetic Law Section Annual Meeting. During the CLE, the speakers will explore liability for induced patent infringement in light of the GSK v. Teva and Amarin v. Hikma & HealthNet decision. The panel will discuss avenues for insurers, PBMs, and pharmacies, as well as generic companies, to reduce the risk of being liable for infringement.
Learn more and register here.
On January 28, 2021, Janet Linn will moderate the CLE “Skinny Labels and Patent Infringement” for the NYSBA Food, Drug & Cosmetic Law Section Annual Meeting. During the CLE, the speakers will explore liability for induced patent infringement in light of the GSK v. Teva and Amarin v. Hikma & HealthNet decision. The panel will discuss avenues for insurers, PBMs, and pharmacies, as well as generic companies, to reduce the risk of being liable for infringement.
Learn more and register here.